Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

ween pirfenidone and placebo in the percentage of patients that experienced a serious adverse event (SAE) and the pattern of adverse events (AEs) was, in general, comparable to that observed in previous clinical studies of pirfenidone.
  • InterMune is preparing an NDA for submission to the FDA in the summer of 2009, to be followed by an MAA submission to the European Medicines Agency (EMEA) around the end of 2009.
  • Results from the CAPACITY studies will be presented in an oral late-breaker session at 3:35 p.m. PDT on May 19 at the International Conference of the American Thoracic Society (ATS) in San Diego.

  • ITMN-191:

    • On January 12, InterMune announced top-line results from a 14-day, Phase 1b study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin).
      • After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. ITMN-191 delivered viral kinetic performance that is comparable to the best results reported to date for other protease inhibitors in similar experiments.
      • There was no evidence of viral rebound during ITMN-191 treatment in any cohort.
      • On April 24, InterMune reported that data from the triple combination study had informed the dose selection for the Phase 2b program of ITMN-191. The Phase 2b trial, expected to begin in the summer of 2009, will study both q12h regimens (600mg and 900mg q12h) and a q8h regimen (300mg q8h) and both 12-week and 24-week treatment durations.

    • At the Annual Meeting of the European Association for the Study of the Liver (EASL
      '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. InterMune to Release First Quarter Financial Results on April 30
    2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    3. InterMune to Present at Canaccord Adams Hepatitis C Conference
    4. InterMune to Present at Citis 4th Annual Biotech Day
    5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    8. InterMune Announces Issuance of U.S. Patent for ITMN-191
    9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
    10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
    11. InterMune to Present at J.P. Morgan Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
    (Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
    (Date:1/22/2015)... January 22, 2015 Dr. Greg Leyer of ... annual Scripps Natural Supplements Pre-Conference seminar on probiotics in San ... an annual continuing education conference for health care professionals. This ... the topic of probiotics in health. Dr. Leyer spoke about ...
    (Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
    Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
    ... added four, six and eight port right-angle BNC connectors to its ... savings as a replacement for applications where a number of single ... ... Sunnyvale, CA (PRWEB) April 29, 2009 -- Regal Electronics ...
    ... - 4TB4Free , ... Austin, Texas (PRWEB) April 29, ... for accessing, storing and distributing content, today announced the release of ... can run virtual CAStor nodes in a single, physical server chassis. ...
    ... MEDX ) is scheduled to host a ... Time on Thursday, April 30, 2009 to review Medarex,s ... of 2009.To access the call live, please dial 1-877-397-0272 ... through the Investor Relations section of Medarex,s website at ...
    Cached Biology Technology:Regal Introduces Four, Six and Eight Port Filtered and Un-Filtered Right Angle BNC Connectors 2Caringo Delivers Storage Cluster in a Box with CAStor 3.0 2Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009 2
    (Date:12/17/2014)... The Defense Logistics Agency is insourcing its efforts ... microcircuits from entering into its supply chain. ... initiative dubbed DNA marking. The capability will validate the ... the supply chain. The new quality control measures will ...
    (Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
    (Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming the travel ... international borders. Over the past decade, ePassports, biometric readers, ... self process through border control via eGates and Automated ... airports, seaports, and land borders across the globe. ...
    Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
    ... N.J. and JAMAICA PLAIN, Mass., April 21, 2009 ... Medarex, Inc. (NASDAQ: MEDX) and Massachusetts Biologic Laboratories ... (UMMS) today announced that they have signed an ... (also known as MDX-066/MDX-1388 and MBL-CDA1/MBL-CDB1), an investigational ...
    ... in the cell and do all sorts of work, but ... know where to go? "There,s no little man sitting ... Arnold, molecular and computational biologist at the USC College of ... them encoded information that tells them where to go in ...
    ... Colorado and TUSTIN, Calif., April 21, 2009--Peregrine ... biopharmaceutical company developing monoclonal antibodies for the ... today reported that two preclinical studies presented ... provided further confirmation of the immunomodulatory mechanisms ...
    Cached Biology News:Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck 2Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck 3Autopilot guides proteins in brain 2Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies 2Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies 3Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies 4
    Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
    "BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
    Request Info...
    Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
    Biology Products: